Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001564590-22-023327 0001846370 XXXXXXXX LIVE 9 Ordinary Shares, nominal value of GBP0.05 per share 06/25/2025 false 0001479615 G8128Y157 Silence Therapeutics Plc 72 Hammersmith Road London X0 W14 8TH Richard Griffiths 44-1534-719761 Floor 1 Liberation Station Esplanade St Helier Y9 JE2 3AS 0001846370 N Richard Ian Griffiths PF N Y9 34543302.00 0.00 34543302.00 0.00 34543302.00 N 24.4 IN * Consists of (i) 19,221,525 ordinary shares represented by American Depositary Shares ("ADSs") held by Ora Capital Limited; (ii) 1,815,522 ordinary shares represented by ADSs held by Sarossa Plc; (iii) 3,967,896 ordinary shares represented by ADSs held by Cream Capital Limited; ; (iv) 300,000 ordinary shares represented by ADSs held by Blake Holdings Limited; (v) 360,000 ordinary shares represented by ADSs held by Ora Ventures Limited; (vi) 190,500 ordinary shares represented by ADSs held by Pinkey's Limited; and (vii) 8,687,859 ordinary shares represented by ADSs held by Mr. Griffiths. Each ADS represents, and at the holder's option is convertible into, three ordinary shares of the Issuer. Mr. Griffiths is a director and the controlling shareholder of each of Ora Capital Limited, Ora Ventures Limited, Blake Holdings Limited, Sarossa Plc and Cream Capital Limited and a controlling shareholder of Pinkey's Limited and possesses the power to direct the voting and disposition of these shares. **This percentage is calculated based upon the 141,690,849 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing. Y Ora Capital Limited WC N Y9 19221525.00 0.00 19221525.00 0.00 19221525.00 N 13.6 CO * Consists of 19,221,525 ordinary shares represented by ADSs held by Ora Capital Limited. **This percentage is calculated based upon the 141,690,849 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing. Ordinary Shares, nominal value of GBP0.05 per share Silence Therapeutics Plc 72 Hammersmith Road London X0 W14 8TH This Amendment No. 9 to Schedule 13D (this "Amendment"), which amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on June 15, 2022, as amended on July 20, 2022, October 20, 2022, August 14, 2023, March 27, 2024, December 18, 2024, March 31, 2025, April 24, 2025 and May 8, 2025 (the "Schedule 13D") on behalf of Richard Ian Griffiths, relates to the ordinary shares, nominal value GBP0.05 per share (the "Shares"), of Silence Therapeutics plc (the "Issuer"). This Amendment is being filed to reflect the open market transactions of the Issuer's ADSs by the Reporting Person together with dilution as a result of an increase in the share capital of the Issuer. Except as amended and supplemented hereby, the Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Schedule 13D. Richard Griffiths Floor 1 Liberation Station, Esplanade, St Helier, Jersey, JE2 3AS m/a n/a Jersey, Channel Islands Mr. Griffiths purchased an aggregate of 543,581 ADSs in open market transactions between May 8, 2025 and June 24, 2025 for an aggregate price of $2.7M. All purchases were for cash and were funded by companies or personal funds of Mr. Griffiths. n/a A. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. B. Schedule 1 Transactions in ADSs During the Past Sixty Days Richard Ian Griffiths /s/ Richard Ian Griffiths Richard Ian Griffiths 06/25/2025 Ora Capital Limited /s/ Richard Ian Griffiths Director 06/25/2025